×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: Food and Drug Administration | COVID-19 vaccination | Merck | Pfizer | Roche

FDA to Review Merck's COVID-19 Vaxx: Bloomberg

Merck
(AP)

Thursday, 14 October 2021 01:06 PM EDT

The U.S. Food and Drug Administration will send drugmaker Merck & Co's experimental COVID-19 antiviral drug to a panel of its outside advisers for a review, Bloomberg News reported on Thursday, citing a person familiar with the plans.

The advisory committee will weigh in on molnupiravir's safety concerns, which have been raised by some experts, before the FDA makes a decision on authorization of the drug, the report said.

Merck earlier this week said it filed for U.S. emergency use authorization for molnupiravir to treat mild-to-moderate patients of COVID-19, putting it on course to become the first oral antiviral medication for the disease.

Merck, Pfizer, Roche -- All in Race for a Pill

Pfizer Inc and Swiss drugmaker Roche Holding AG are also racing to develop an easy-to-administer antiviral pill for COVID-19.

Merck is developing molnupiravir in partnership with U.S.-based Ridgeback Biotherapeutics.

In early October, data showed Merck's drug could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, pummeling shares of coronavirus vaccine makers.

The FDA and Merck did not immediately respond to Reuters' requests for comment.

© 2023 Thomson/Reuters. All rights reserved.


StreetTalk
The U.S. Food and Drug Administration (FDA) will send drug maker Merck & Co.'s experimental COVID-19 antiviral drug to a panel of its outside advisers for a review, Bloomberg News reported on Thursday, citing a person familiar with the plans.
Food and Drug Administration, COVID-19 vaccination, Merck, Pfizer, Roche
186
2021-06-14
Thursday, 14 October 2021 01:06 PM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Get Newsmax Text Alerts
TOP

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved